Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human, Phase 1, Open-Label Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 4A10 Monotherapy In Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT07586618 is registered in ClinicalTrials.gov with Allterum Therapeutics, Inc as lead sponsor.

NCT NCT07586618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07586618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human, Phase 1, Open-Label Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 4A10 Monotherapy In Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Lead sponsor
Allterum Therapeutics, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2026
Completion date
September 30, 2028
Enrollment
24 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia all, lymphoblastic lymphoma